Infectious Disease Diagnostics Market Size, Share, Growth, Report 2025 to 2034

Infectious Disease Diagnostics Market Size and Growth Factors 2025 to 2034

The global infectious disease diagnostics market size was estimated at USD 26.53 billion in 2024 and is expected to be worth around USD 62.71 billion by 2034, expanding at a compound annual growth rate (CAGR) of 8.98% over the forecast period from 2025 to 2034. In hospitals, diagnostic centers, and homecare settings, the need for quick and efficient evaluation of infections and the control of infections enhances the need for effective and timely diagnostics for infectious diseases. The growing awareness of hospital-acquired infections, coupled with the increasing incidence of chronic and infectious diseases, facilitates the use of single use sterile diagnostic instruments that aid in the prevention cross contamination and cross infection. The rise of homecare services and the use disposable gloves, masks, syringes, and point of care diagnostic kits, motivates the use of diagnostic instruments. The need for sustainable and eco-friendly diagnostic depends on the use of disposable instruments for diagnostic procedures or infection control and care.

The shifting of technological strategies is fostering the changed paradigm of the different markets. The use of AI, automation, and IoT in manufacturing processes has positively impacted the quality of products, efficiency, safety of the patients, and operations within a healthcare facility. The lack of responsibility, authoritarian laws regarding markets with increased investment in the healthcare sector is positively impacting markets on the rise. The pivot of the healthcare industry to more decentralized and value directed systems, the demands will only grow in the coming years regarding the affordability and the integration of new technology to diagnostics.

Report Highlights

• By Region – North America (37.8%): Leading due to advanced healthcare infrastructure, high adoption of single-use disposables, strong government infection control programs, and growing outpatient and home healthcare services.
• By Product Type – Disposable Gloves (36.5%): Highest among products due to widespread use in infection prevention across hospitals, diagnostic centers, and home care settings.
• By Material Type – Plastic-Based Disposables (PP, PE, PVC) (59.1%): Preferred for durability, cost-efficiency, and widespread adoption across healthcare facilities.
• By End User – Hospitals & Clinics (40.2%): Lead adoption because of high patient volumes, procedural and surgical needs, and investment in advanced disposables for infection prevention.
• By Technology – RFID-Enabled/Smart Devices (20.60%): Widely adopted for inventory management, traceability, and operational efficiency in hospitals and laboratories.

Market Trends

• Increased Emphasis on Infection Control: More and more people are getting infectious diseases and chronic illnesses. That's why more hospitals and diagnostic centers need to take care of more people and offer more services to homecare clients. More hospitals and diagnostic centers are moving to use more single-use and sterile items such as gloves, masks, and gowns. This is to lessen the risks of contamination and keep patients safe. There is more disposable equipment use, such as point-of-care diagnostic kits, because people are more aware of the need for and use of stricter contamination control. More people are getting care in their homes, and more people are using telemedicine, which means more people are using healthcare facilities that are connected to the hospital and are less centralized. Everyone needs to use and stick to the proper hygiene protocols to keep their infections from spreading. This is true in both wealthy and less wealthy countries, which means that proper disposable equipment and certain diagnostic tools need to be used more and more.
• Responsible Product Introductions and Innovation: To make improvements in safety, performance, and environmental considerations, innovation, sustainability, and strategic collaborations are shifting the focus of manufacturers in the industry. To promote sustainable healthcare and reduce medical waste, 3M, Medline industries and Smith & Nephew developed and released biodegradable and eco-friendly disposable solutions as early as 2024, and as late as 2025. In June 2025, Becton Dickenson (BD) released smart connected syringes with RFID technology to improve inventory management, traceability and overall safety of patients in hospitals and clinics. Partnerships with hospitals and support for the sustainable use of materials have led to the creation of recyclable, eco-friendly diagnostics. Environmental responsibly, integrating smart disposables and the use of therapeutic claim antimicrobial and antiviral layers for contamination safety and diagnostic reliability and accuracy are accelerating.

Report Scope

Market Dynamics

Market Drivers

• Health Initiatives and Safety Standards: Major economies have implemented stricter infection control policies and healthcare programs to promote the use disposables. The U.S. Department of Health and Human Services (HHS) and the European Commission took significant steps to standardize the quality of disposables and improve the disposal of medical waste. Initiatives like these, along with the hospital accreditation processes focused on the maintenance of hygiene, have fostered the use of single-use diagnostics in public and private healthcare facilities.
• Hospitalization and Surgical Volume Increases: The increase in surgical procedures, diagnostic tests and emergency admissions on a global scale drives the need for medical disposables. In 2025, the need was especially in the Asia-Pacific, Latin America, and Middle East regions where the growth of ambulatory surgical centers and short-stay procedures focuses on cost efficiency, patient safety, and hygiene compliance. The increase in use of disposables such as gowns, drapes, catheters and wound dressings in these regions indicates a strong relationship between the healthcare infrastructure and the use of disposables.

Market Restraints

• Environmental Issues and Waste Disposal: Infection-disease diagnostics are required to be single-use to maintain and control hygiene, but this practice generates a lot of biomedical waste, causing waste and environmental concerns. This will remain a notable problem in developing countries in 2025, which also have limited waste separation and disposal facilities. This continues to be a problem in developing countries and will remain so in 2025 and beyond if affordable biodegradable and recyclable waste options are not developed. Infection control and sustainability are still not adopted on a widescale, yet biodegradable and recyclable options for waste remain commercially scarce.
• High Production and Procurement Costs: Due to the increase in raw material prices, disruptions in the global supply chain and manufacturing complexities, in 2025, the costs associated with the production of biomaterials disposable products also increased, and they also became less affordable for smaller healthcare providers and low-income regions. As late as 2025, the hospital associations in these regions of Africa and Southeast Asia stated that the costs associated with the disposables are increasing so much that they are preventing the use of disposables completely; this is a notable barrier to advancements and growth within this region.

Market Challenges

• Supply Chain Vulnerabilities: The COVID-19 pandemic revealed weaknesses in our supply chains that are still apparent in 2025, particularly our dependence on foreign raw material and the logistical delays that accompany such imports. The ongoing unfilled demand for critical disposables and intermittent supply shortages of other essential materials have led some manufacturers to seek localized production. Nevertheless, efforts to cut reliance on global supply chains are often time- and resource-intensive.
• Regulatory Compliance and Standardization: The market for diagnostic testing and disposables needed to detect infectious diseases is tightly regulated on a regional and national basis in terms of safety, sterilization, and performance criteria, as well as in other market-entry/range activities. Compliance with these standards tends to prolong the time to market for new disposables. In 2025, companies looking to launch disposable diagnostic technologies in Asia-Pacific regions experienced slower regulatory approval processes than those available in North America and Europe, further complicating global expansion efforts.

Market Opportunities

• Eco-Friendly and Intelligent Disposable Products: A shifting mindset towards environmentally-aligned disposable products drives the development of biodegradable and recyclable materials for gloves, gowns, and packaging. By mid-2025, companies like Cardinal Health and Medtronic will have invested in eco-friendly manufacturing facilities and will have released compostable disposable products. The placement of smart technologies like RFID and QR codes fosters better inventory control, waste reduction in hospitals and disposables traceability, enabling additional efficiency improvements.
• Home Care Healthcare: The expansion of healthcare access in India, Brazil, and Indonesia in 2025, be, in part, the driver for demand on single-use diagnostics and therapeutics. Disposable products sustain healthcare infrastructure and home-based care with remote patient monitoring increasing and the adoption of permanent home care growing. Emerging markets with growing healthcare expenditures and heightened patient awareness will fuel the growth of the market for the remainder of the decade.

Regional Analysis

The infectious disease diagnostics market is segmented into several key regions: North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa). Here’s an in-depth look at each region.

North America takes greatest portion

• The North America infectious disease diagnostics market size was valued at USD 10.03 billion in 2024 and is expected to reach around USD 23.70 billion by 2034.

The North America takes the greatest portion because of the well-developed healthcare system and the high priority on infection prevention. More than 70% of U.S. hospitals and ambulatory surgical centers (ASCs) had confirmed by March 2025 an expansion of their usage of environmentally friendly single-use items (gloves, gowns, and syringes, among others). In February 2025, the use of disposable products was further encouraged through the CDC Infection Control Funding Program that was launched in hospitals and outpatient facilities. Leaders in the market such as 3M, Becton Dickinson (BD) and Cardinal Health were producing recyclable and biodegradable disposables to achieve internal sustainability goals. Demand has been also triggered by the expansion of outpatient and home care medical services. The focus of the region on healthcare innovation and the fast adoption of the latest technologies makes North America the leader in the adoption of products and industry.

Europe is the second largest market

• The Europe infectious disease diagnostics market size was estimated at USD 7.35 billion in 2024 and is projected to surpass around USD 17.37 billion by 2034.

Europe is the second largest market that is backed by stringent hygiene laws and sustainability programs. In April 2025, nonwoven disposables such as Germany, France, and the U.K., had shifted to biodegradable items in healthcare facilities in accordance with Green Healthcare Directive of the EU. The higher expenditures during March 2025 on the waste management and infection prevention in hospitals only further enhanced the use of single-use diagnostics. The companies like Paul Hartmann AG, Mollnlyke Health Care and Smith and Nephew have intensified their relationships with the national health care systems in order to have reliable delivery of sterile products. Economic growth is facilitated by the interest of the European Commission in the processes of the circular economy and the environmentally more efficient production, and the stability in the market growth is ensured by the regulatory power of the region and its interest to ensuring healthcare eco-friendliness.

Asia-Pacific is experiencing high growth

• The Asia-Pacific infectious disease diagnostics market size was accounted for USD 6.74 billion in 2024 and is expected to hit around USD 15.93 billion by 2034.

The Asia-Pacific is experiencing high growth rate because of government incentives, the increasing healthcare infrastructure and the increased awareness of infection control by the people. By May 2025, 40 percent of the world will require disposable masks and gloves, and this compartment was comprised of India, China, and Japan. On June 2025, China and South Korea had public-private partnerships to enhance domestic manufacturing of infection prevention products and home health. Increasing hygienic awareness and increasing prevalence of chronic diseases in other countries such as Thailand and Vietnam also helped the demand. Existing companies such as Nipro, Medline, and Terumo developed regional manufacturing to build the supply chain in both the local and international market. The momentum of market leadership of the region is still supported by modernization of healthcare systems and well-developed production base.

Market Share, By Region, 2024 (%)

LAMEA region is growing well

• The LAMEA infectious disease diagnostics market was valued at USD 2.41 billion in 2024 and is anticipated to reach around USD 5.71 billion by 2034.

The LAMEA region is growing well because of the maturing hospital infrastructure and rising investments in the area related to the population health. Other nations including Brazil, UAE, South Africa started using sterile disposable kits in surgical and diagnostic use by April 2025. The aim to decrease the level of import reliance promoted the domestic production and sterilization. In May 2025, the Saudi Health Initiative helped in the automation of preventing infection and waste management in healthcare facilities. With increasing hygienic awareness, chronic disease treatment is becoming more important, and healthcare changes are taking place, LAMEA will be among the areas of growth in infectious disease diagnostics after 2026.

Segmental Analysis

Product Type Analysis

Wound Management Products: These are bandages, gauzes, and dressings needed for surgical aftercare and managing chronic wounds. By April 2025, hospitals and clinics in North America and Europe were increasing their orders for advanced wound dressings with antimicrobial properties, aimed at preventing infections and aiding in quicker recovery. Smith & Nephew and 3M launched hydrocolloid and foam dressings to elevate patient comfort and minimize the frequency of dressing changes.

Drug Delivery Disposables: Syringes, IV sets, and catheters are integral to the precise delivery of medications and fluids. By February 2025, healthcare professionals in the U.S. and India noted the greater use of prefilled syringes and safety IV catheters to cut down the risk of contamination and needle-stick injuries. In May 2025, Becton Dickinson (BD) launched disposable, eco-friendly catheters, encouraging hospitals to adopt greener practices.

Market Share, By Product Type, 2024 (%)

Diagnostic & Laboratory Disposables: For molecular testing, diagnostic specimen containers, collection kits, and pipette tips are necessary. In June 2025, diagnostic centers in Europe and the Asia-Pacific region experienced high demand for rapid test cartridges and disposable pipette filters to facilitate testing for infectious diseases. Thermo Fisher Scientific and Qiagen expanded their range of disposable kits to boost automation efficiency in labs.

Dialysis and Infusion Disposables: Used in renal and critical care, this includes dialysis filters, tubing sets, and infusion bags. In March 2025, Fresenius Medical Care announced next generation single-use dialyzers that enhanced filtration and lowered the infection risks. With rising chronic kidney disease in Southeast Asia and Latin America, regional implementation of these products occurred.

Incontinence and Sterilization Products: In aged care, the infection control effectiveness of disposable adult diapers, underpads, and sterilization wraps cannot be overstated. Demand for eco-friendly hygiene products, especially framed within the Kyoto Protocol, has particularly increased in Japan and Europe. By May 2025, this has prompted Kimberly-Clark’s focus on developing more biodegradable solutions aimed at comfort, hygiene, and ecological sensitivity.

Materials Analysis

Plastic Resins: Polypropylene, polyethylene, and PVC are rapidly employable disposable medical items and these are the three most used resins in the disposable medical items as they are durable, resistant to chemicals and are cost-effective. By January 2025, most recyclables and medical disposable resins are used as disposable medical items and initiatives in recyclable disposable medical items. Bio-based polypropylene is used in Europe Plants and these reduce environmental impact. Becton Dickinson and 3M are the most use disposable resins in syringes, catheters, and diagnostic consumables.

Nonwoven Materials: Infection control and barrier protection is provided by masks, gowns, drapes and operating room covers. These are Nonwoven fabrics. These Masks are made of high filtration non woven materials which was adapted in North America and Asia Pacifc regions by March 2025. DuPont and Ahlstrom-Munksjo were the companies which made innovative non woven surgical barrier in composites.

Paper & Paperboard: Paper materials are used for packaging, sterilization wraps and for enclosed test kits. In April 2025, Germany and South Korea were the eco friendly manufacturers which expanded biodegradable medical packaged to minimize waste. For hospital eco sustainability to minimize waste, sterilize and protect diagnostic consumables packaged in approved waste was the trend.

Glass and rubber materials: Glass and rubber materials used for syringes, vials, and for the rubber part of the stopper systems are due to their thermal resistance as well as chemical stability. They are also compatible with vaccines and drugs that are injectable. These materials were in high demand all over the world as the increased use of advanced prefilled syringes and diagnostic kits were adopted in hospitals and laboratories. These suppliers place an emphasis on the quality of these materials being safe and efficacious. This demand started in May of 2025 and was fueled during the vaccine and therapeutic procedures.

End User Analysis

Hospitals and Clinics: Hospitals have been major consumers of diagnostic consumables specially designed for the protection of healthcare workers and patients from infections. By June 2025, large chains of hospitals in U.S. and Europe, purchased in large quantities, single-use surgical kits, disposable catheters and PPE. This reduced cross-contamination and improved hospital operational efficiency. Hospital automation diagnostic kits are also commercially available to help hospitals cope with high patient volumes and rapidly available results.

Home Healthcare: The demand for home healthcare products continues to grow due to the increasing aged population and chronic diseases. By April 2025, Medline and Cardinal Health, homecare kits (&IV lines, wound care consumables and diagnostic test kits) became available. These kits enabled patient monitoring of diabetes and chronic infections at home, decreasing the need for hospital visits, confirming support of сentralized healthcare.

Ambulatory Surgical Centers (ASCs): ASCs are readily utilizing, single-use instruments, sterile drapes and gowns for minor surgical surgeries. By May 2025, the ASCs in the U.S. and Japan adopted disposable-laparoscopic instruments and disposable-surgical kits. This strategy was aimed at cost reduction of sterilization, operational efficiency and hygiene. This practice encourages quick surgical procedure turnarounds and reduces risk of infection.

Diagnostic Centers & Laboratories: For high-volume testing, including molecular and rapid diagnostic tests, diagnostic labs use disposable sample tubes, test kits, and pipette tips. By July 2025, AI-integrated disposable kits were adopted by laboratories in North America and Europe, enhancing accuracy, automating workflows, reducing contamination, and minimizing the need for manual lab work. To meet the growing need for testing for infectious diseases, Thermo Fisher Scientific and Qiagen have broadened their product offerings.

Application Analysis

Managing Cardiovascular Conditions: ECG electrodes, disposable catheters, and pressure monitoring kits are essential components in cardiovascular care. Advanced single-use hemodynamic monitoring systems that assess the hemodynamic parameters improve real-time monitoring of the cardiac systems and are integrated within North American hospitals’ cardiovascular care infrastructure focusing on patient safety and efficiency within the procedural frameworks.

Managing Diabetes and Chronic Diseases: Hybrid reusable and disposable systems for in-home monitoring for integrated care of diabetes using continuous glucose monitoring systems, insulin delivery systems, and lancets are integral. Healthcare systems for the Asia-Pacific are expanding diabetic care systems under the hybrid reusable and disposable models focusing on improved disease management and lower reliance on the hospital in the continuum of care by April 2025.

Controlling Infectious Diseases: PPE, masks, gloves, and test kits are integral components in the continuum of infection control. The rise in monitoring for influenza and COVID-19 in Europe increased demand for high-barrier disposable protective equipment by May 2025. Advanced cross infection control measures including the use of disposable sampling systems, rapid diagnostics and integrated protective equipment were introduced in hospitals and clinics for high risk areas.

Surgical and Postoperative Care: Pre-packed single-use surgical kits, disposable scalpels and wound dressings are crucial in maintaining sterile procedures and infection control. By June 2025, the use of disposable antimicrobial wound care products became integrated systems for enhancing post-operative recovery along with disposable kits within Latin American and Indian hospitals.

Infectious Disease Diagnostics Market Top Companies

• 3M
• Becton Dickinson
• Medline Industries
• Smith & Nephe
• Thermo Fisher Scientific
• Qiagen
• Paul Hartmann AG
• Mölnlycke Health Care
• Nipro Corporation
• Terumo Corporation

Recent Developments

• In January 2024, QIAGEN launched two new syndromic testing panels for its QIAstat-Dx platform in India—the Gastrointestinal Panel 2 and the Meningitis/Encephalitis Panel—receiving CDSCO regulatory approval in January 2024, which enables healthcare providers to diagnose infectious diseases rapidly and accurately. These panels join the previously authorized Respiratory SARS-CoV-2 Panel and use multiplex real-time PCR technology to identify a range of pathogens from a single sample, with results available within 80 minutes for central nervous system infections and in about an hour for gastrointestinal diseases, significantly improving speed and reliability over traditional methods. The QIAstat-Dx system offers scalable formats and remote connectivity via the QIAsphere platform for efficient lab management, supporting improved patient outcomes and reducing the burden on healthcare systems across India.

Market Segmentation

By Product Type

• Disposable Gloves
• Masks & Respirators
• Syringes & Needles
• Gowns & Drapes
• Point-of-Care Diagnostic Kits
• Catheters
• Wound Dressings

By Material Type

• Plastic-Based Disposables
• Biodegradable / Eco-Friendly Materials
• Intelligent / Smart Materials

By Technology

• RFID-Enabled / Smart Devices
• IoT-Connected Devices
• Automated / AI-Integrated Diagnostics

By End User

• Hospitals and Clinics
• Diagnostic Centers/Labs
• Home Healthcare
• Ambulatory Surgical Centers

By Region

• North America
• APAC
• Europe
• LAMEA